Arvinas (ARVN) Competitors $9.61 +0.34 (+3.67%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$9.56 -0.05 (-0.57%) As of 10/3/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. TARS, IBRX, BEAM, CDTX, BHC, CPRX, IDYA, BLTE, AGIO, and IRONShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Tarsus Pharmaceuticals (TARS), ImmunityBio (IBRX), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Bausch Health Cos (BHC), Catalyst Pharmaceuticals (CPRX), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Agios Pharmaceuticals (AGIO), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Tarsus Pharmaceuticals ImmunityBio Beam Therapeutics Cidara Therapeutics Bausch Health Cos Catalyst Pharmaceuticals IDEAYA Biosciences Belite Bio Agios Pharmaceuticals Disc Medicine Tarsus Pharmaceuticals (NASDAQ:TARS) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Does the media favor TARS or ARVN? In the previous week, Arvinas had 3 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 5 mentions for Arvinas and 2 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.62 beat Arvinas' score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TARS or ARVN more profitable? Arvinas has a net margin of -19.47% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Arvinas' return on equity of -12.01% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Arvinas -19.47%-12.01%-6.97% Which has stronger valuation & earnings, TARS or ARVN? Tarsus Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M15.04-$115.55M-$2.33-27.97Arvinas$263.40M2.68-$198.90M-$1.01-9.51 Which has more volatility & risk, TARS or ARVN? Tarsus Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Do analysts prefer TARS or ARVN? Tarsus Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 2.30%. Arvinas has a consensus target price of $16.18, indicating a potential upside of 68.41%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Arvinas 1 Sell rating(s) 11 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.48 Do institutionals and insiders have more ownership in TARS or ARVN? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryArvinas beats Tarsus Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$705.55M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E Ratio-9.5122.2886.9626.71Price / Sales2.68458.33604.82131.77Price / CashN/A47.8637.9061.31Price / Book1.189.9312.556.55Net Income-$198.90M-$52.80M$3.31B$277.50M7 Day Performance16.20%5.22%4.28%2.42%1 Month Performance22.73%10.61%6.90%8.63%1 Year Performance-61.50%25.03%70.54%31.60% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.1179 of 5 stars$9.61+3.7%$16.18+68.4%-61.5%$705.55M$263.40M-9.51420TARSTarsus Pharmaceuticals0.78 of 5 stars$58.08+3.2%$66.67+14.8%+92.3%$2.45B$182.95M-24.9350IBRXImmunityBio2.6914 of 5 stars$2.57+1.2%$10.75+318.3%-25.9%$2.43B$56.60M-5.35590BEAMBeam Therapeutics2.8889 of 5 stars$23.91+4.1%$46.40+94.1%+10.0%$2.42B$63.52M-5.31510CDTXCidara Therapeutics3.9745 of 5 stars$95.26+5.3%$119.43+25.4%+835.7%$2.42B$1.27M-8.5690Analyst ForecastHigh Trading VolumeBHCBausch Health Cos4.6486 of 5 stars$6.47-0.2%$9.00+39.1%-19.7%$2.40B$9.63B24.8920,700CPRXCatalyst Pharmaceuticals4.8597 of 5 stars$19.55+0.2%$33.20+69.8%+4.2%$2.39B$491.73M11.8580News CoverageAnalyst DowngradeBuyback AnnouncementIDYAIDEAYA Biosciences4.3117 of 5 stars$27.19+1.3%$43.36+59.5%-7.8%$2.38B$7M-7.1780Positive NewsAnalyst UpgradeBLTEBelite Bio3.0187 of 5 stars$73.00+4.3%$96.00+31.5%+48.3%$2.32BN/A-47.1010Positive NewsAGIOAgios Pharmaceuticals4.4461 of 5 stars$39.27+0.9%$56.00+42.6%-2.0%$2.28B$36.50M3.57390Insider TradeIRONDisc Medicine2.0187 of 5 stars$65.06-0.7%$98.30+51.1%+35.8%$2.26BN/A-14.5530 Related Companies and Tools Related Companies TARS Competitors IBRX Competitors BEAM Competitors CDTX Competitors BHC Competitors CPRX Competitors IDYA Competitors BLTE Competitors AGIO Competitors IRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts